Join Now!

Begin our membership application process today!

Contact Us                                                                                                        

Kena Norris
Executive Director

312.227.7406
knorris@ccpapp.org

Priya Stemler
Director of Operations

312.227.7437
pstemler@ccpapp.org

Paresh Patel
National Sales Manager

312.227.7436
papatel@ccpapp.org

Jennifer Jackson
Sr. Administrative Assistant
312.227.7442
jdjackson@ccpapp.org
 
Sonia Perez Gandara
Member Relations Specialist

312.227.7508
sgandara@ccpapp.org

General Inquiries:
312.227.7444
info@ccpapp.org
 
 

Merck Adult Vaccine Information - Informational Flyer (April 2016)

CCPAPP would like to remind members of the various immunization resources offered by Merck, including those which provide helpful information for adult patients on Zostavax (Zoster Vaccine Live) and Pneumovax 23 (Pnuemococcal Vaccine Polyvalent).     
 
ZOSTAVAX (Zoster Vaccine Live): Although 99.5% of adults aged 40 or older are at risk for zoster (1), 75% of adults aged 60 or older reported not having received vaccination against zoster (2). Please see Merck's Zostavax Detail Aid to review the clinical reasons to vaccinate against zoster.
 
PNEUMOVAX 23 (Pnuemococcal Vaccine Polyvalent): As many providers know, Pneumovax 23 is approved for adults aged 50 years or older; however, please be reminded that the CDC recommends Pneumovax 23 for patients aged 19-64 years with certain chronic conditions (2). Please see Merck's Pneumovax 23 Detail Aid to review the clinical reasons to vaccinate against pneumococcal disease, especially for appropriate adult patients at increased risk.

Resources: 
(1) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30. 

(2) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30. 

(3) Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816-819.
 

« Back

 
 

 

 

logo_Merck[1]

header_logo_sp[1]

 

 

LOGO_MMS

 

 

 

 
Copyright © 2019 CCPA Purchasing Partners. All rights reserved.
Web site design and development by Americaneagle.com